Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial

Young Suk Lim, Yung Sang Lee, Geum Youn Gwak, Kwan Soo Byun, Yoon Jun Kim, Jonggi Choi, Jihyun An, Han Chu Lee, Byung Chul Yoo, So Young Kwon

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir. Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear. Among 192 patients with HBV-resistance mutations to ETV and/or adefovir, who were randomized to receive TDF monotherapy (n = 95) or TDF/ETV combination therapy (n = 97) for 48 weeks, 189 agreed to continue TDF monotherapy (TDF-TDF group) or to switch to TDF monotherapy (TDF/ETV-TDF group) and 180 (93.8%) completed the 144-week study. Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80). At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46). By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144. Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence. At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV. No patients developed additional resistance mutations throughout the study period. Conclusion: TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV. (Hepatology 2017;66:772–783).

Original languageEnglish
Pages (from-to)772-783
Number of pages12
JournalHepatology
Volume66
Issue number3
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Tenofovir
Chronic Hepatitis B
Hepatitis B virus
Pharmaceutical Preparations
Mutation

ASJC Scopus subject areas

  • Hepatology

Cite this

Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B : 3-year trial. / Lim, Young Suk; Lee, Yung Sang; Gwak, Geum Youn; Byun, Kwan Soo; Kim, Yoon Jun; Choi, Jonggi; An, Jihyun; Lee, Han Chu; Yoo, Byung Chul; Kwon, So Young.

In: Hepatology, Vol. 66, No. 3, 01.09.2017, p. 772-783.

Research output: Contribution to journalArticle

Lim, YS, Lee, YS, Gwak, GY, Byun, KS, Kim, YJ, Choi, J, An, J, Lee, HC, Yoo, BC & Kwon, SY 2017, 'Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial', Hepatology, vol. 66, no. 3, pp. 772-783. https://doi.org/10.1002/hep.29187
Lim, Young Suk ; Lee, Yung Sang ; Gwak, Geum Youn ; Byun, Kwan Soo ; Kim, Yoon Jun ; Choi, Jonggi ; An, Jihyun ; Lee, Han Chu ; Yoo, Byung Chul ; Kwon, So Young. / Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B : 3-year trial. In: Hepatology. 2017 ; Vol. 66, No. 3. pp. 772-783.
@article{7ff15fb6f35e48df8cae8fe9a0298644,
title = "Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial",
abstract = "Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir. Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear. Among 192 patients with HBV-resistance mutations to ETV and/or adefovir, who were randomized to receive TDF monotherapy (n = 95) or TDF/ETV combination therapy (n = 97) for 48 weeks, 189 agreed to continue TDF monotherapy (TDF-TDF group) or to switch to TDF monotherapy (TDF/ETV-TDF group) and 180 (93.8{\%}) completed the 144-week study. Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3{\%} in the TDF-TDF group and 68.0{\%} in the TDF/ETV-TDF group (P = 0.80). At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5{\%}, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46). By on-treatment analysis, a total of 79.4{\%} had HBV DNA <15 IU/mL at week 144. Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence. At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV. No patients developed additional resistance mutations throughout the study period. Conclusion: TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV. (Hepatology 2017;66:772–783).",
author = "Lim, {Young Suk} and Lee, {Yung Sang} and Gwak, {Geum Youn} and Byun, {Kwan Soo} and Kim, {Yoon Jun} and Jonggi Choi and Jihyun An and Lee, {Han Chu} and Yoo, {Byung Chul} and Kwon, {So Young}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/hep.29187",
language = "English",
volume = "66",
pages = "772--783",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B

T2 - 3-year trial

AU - Lim, Young Suk

AU - Lee, Yung Sang

AU - Gwak, Geum Youn

AU - Byun, Kwan Soo

AU - Kim, Yoon Jun

AU - Choi, Jonggi

AU - An, Jihyun

AU - Lee, Han Chu

AU - Yoo, Byung Chul

AU - Kwon, So Young

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir. Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear. Among 192 patients with HBV-resistance mutations to ETV and/or adefovir, who were randomized to receive TDF monotherapy (n = 95) or TDF/ETV combination therapy (n = 97) for 48 weeks, 189 agreed to continue TDF monotherapy (TDF-TDF group) or to switch to TDF monotherapy (TDF/ETV-TDF group) and 180 (93.8%) completed the 144-week study. Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80). At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46). By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144. Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence. At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV. No patients developed additional resistance mutations throughout the study period. Conclusion: TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV. (Hepatology 2017;66:772–783).

AB - Combination therapy has been recommended for the treatment of patients harboring multiple drug-resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir. Nonetheless, whether prolonged TDF monotherapy would be safe and increase the virologic response rate in these patients was unclear. Among 192 patients with HBV-resistance mutations to ETV and/or adefovir, who were randomized to receive TDF monotherapy (n = 95) or TDF/ETV combination therapy (n = 97) for 48 weeks, 189 agreed to continue TDF monotherapy (TDF-TDF group) or to switch to TDF monotherapy (TDF/ETV-TDF group) and 180 (93.8%) completed the 144-week study. Serum HBV DNA <15 IU/mL at week 48, the primary efficacy endpoint, was achieved in 66.3% in the TDF-TDF group and 68.0% in the TDF/ETV-TDF group (P = 0.80). At week 144, the proportion with HBV DNA <15 IU/mL increased to 74.5%, which was significantly higher compared with that at week 48 (P = 0.03), without a significant difference between groups (P = 0.46). By on-treatment analysis, a total of 79.4% had HBV DNA <15 IU/mL at week 144. Transient virologic breakthrough occurred in 6 patients, which was due to poor drug adherence. At week 144, 19 patients who had HBV DNA levels >60 IU/mL qualified for genotypic resistance analysis, and 6 retained some of their baseline resistance mutations of HBV. No patients developed additional resistance mutations throughout the study period. Conclusion: TDF monotherapy was efficacious and safe for up to 144 weeks, providing an increasing rate of virologic response in heavily pretreated patients with multidrug-resistant HBV. (Hepatology 2017;66:772–783).

UR - http://www.scopus.com/inward/record.url?scp=85021248777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021248777&partnerID=8YFLogxK

U2 - 10.1002/hep.29187

DO - 10.1002/hep.29187

M3 - Article

C2 - 28370419

AN - SCOPUS:85021248777

VL - 66

SP - 772

EP - 783

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -